<DOC>
	<DOCNO>NCT01953367</DOCNO>
	<brief_summary>This study investigate bioequivalence compare safety profile follow inhalation Vantobra TOBI nebulizer solution healthy subject . Bioequivalence investigate base pharmacokinetic plasma profile Vantobra nebulizer solution compare TOBI nebulizer solution .</brief_summary>
	<brief_title>Bioequivalence Safety Vantobra TOBI Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Tobramycin</mesh_term>
	<criteria>Male female healthy subject ethnic origin Aged 18 50 year age Body weight â‰¥50 kg body mass index ( BMI ) 18.5 29 kg/m2 FEV1 &gt; 90 % predict Able demonstrate correct inhaler use Written inform consent History clinically relevant allergy idiosyncrasy tobramycin inactive ingredient ( ) IMP Any history drug hypersensitivity , asthma , urticaria , significant allergic diathesis . Any evidence cardiovascular , pulmonary , renal , hepatic , gastrointestinal , hematological , endocrinological , metabolic , neurological , psychiatric disease screen Surgery gastrointestinal respiratory tract might interfere drug absorption History malignancy within past 5 year History orthostatic hypotension , faintings blackouts Acute chronic viral , bacterial fungal airway infection , include laryngeal infection , mouth throat infection , hoarseness ; Other clinically relevant chronic acute infectious illness Clinical chemical , hematological laboratory parameter clinically relevant outside normal range</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>AUC</keyword>
	<keyword>Cmax</keyword>
</DOC>